Application of rhenium-188 HEDP in bone metastases therapy.

Abstract

Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less radiotoxic and more effective radiopharmaceuticals is therefore a challenge for radiopharmacists and industry. This paper reviews the application of rhenium-188 HEDP as a reactor- or generator-produced nuclide for bone metastases therapy.

• Authors: Justyna Scheffler, Mirosława Derejko, Tomasz Bandurski, Grzegorz Romanowicz
• Journal: Nuclear medicine review. Central & Eastern Europe (Nucl Med Rev Cent East Eur) Vol. 6 Issue 1 Pg. 55-7 ( 2003) ISSN: 1506-9680 [Print] Poland
• PMID: 14600935 (Publication Type: Journal Article, Review)

Chemical References

• Organometallic Compounds
• Radiopharmaceuticals
• rhenium-186 HEDP
• Rhenium
• Etidronic Acid

Topics

• Bone Neoplasms (complications, radiotherapy, secondary)
• Etidronic Acid (adverse effects, therapeutic use)
• Humans
• Leukopenia (etiology)
• Organometallic Compounds
• Pain (etiology, radiotherapy)
• Palliative Care (methods)
• Practice Patterns, Physicians'
• Radiopharmaceuticals (therapeutic use)
• Rhenium (adverse effects, therapeutic use)
• Thrombocytopenia (etiology)
• Treatment Outcome